Proactive Investors CEO interview
We are pleased to share an interview with CEO Dr David Solomon following the acquisition of Sanmirna and how it transforms Thalia into a clinical stage RNS therapeutics business.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be visible to everyone.
Investor Q&As
Start the conversation
Ask Thalia Therapeutics a question about this update.